Acquired inhibitors of coagulation factors: Part II

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 5, 2012, Pages 447-453

  Franchini, Massimo ^a   Lippi, Giuseppe ^b   Favaloro, Emmanuel J ^c  

^a Department of Transfusion Medicine   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

acquired hemophilia; autoantibodies; bleeding; inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMIODARONE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AUTOANTIBODY; BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING INHIBITOR; CEPHALOSPORIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; PENICILLIN DERIVATIVE; PHENYTOIN; PROTHROMBIN COMPLEX; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; TETRACYCLINE DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; HEMOPHILIA A; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; DRUG ANTAGONISM; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; HEMOPHILIA A; HUMANS;

EID: 84872904381     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1305779     Document Type: Article

References (85)

1. Watson H. G., Chee Y. L., Greaves M. Rare acquired bleeding disorders. Rev Clin Exp Hematol: 2001; 5 4 405 429, quiz 431 (Pubitemid 34947698)
2. Bouvry P., Recloux P. Acquired hemophilia. Haematologica: 1994; 79 6 550 556
3. Cohen A. J., Kessler C. M. Acquired inhibitors. Baillieres Clin Haematol: 1996; 9 2 331 354 (Pubitemid 26185952)
4. Franchini M., Veneri D. Acquired coagulation inhibitor-associated bleeding disorders: an update. Hematology: 2005; 10 6 443 449 (Pubitemid 43123466)
5. Franchini M., Targher G., Montagnana M., Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta: 2008; 395 1-2 14 18
6. Franchini M., Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis: 2011; 31 4 449 457
7. Lippi G., Favaloro E. J., Montagnana M., Manzato F., Guidi G. C., Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis: 2011; 22 3 160 166
8. Knöbl P., Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol: 1998; 11 2 305 318 (Pubitemid 29103546)
9. Favaloro E. J., Posen J., Ramakrishna R., et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis: 2004; 15 8 637 647 (Pubitemid 39612969)
10. Miesbach W., Voigt J., Peetz D., Scharrer I. [Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin]. Med Klin (Munich): 2003; 98 6 339 343 (Pubitemid 36806752)
11. Lucia J. F., Aguilar C. A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia: 2005; 11 2 178 180 (Pubitemid 40468068)
12. Takahashi H., Fuse I., Abe T., Yoshino N., Aizawa Y. Acquired factor V inhibitor complicated by Hashimoto's thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis: 2003; 14 1 87 93 (Pubitemid 36206729)
13. Emori Y., Sakugawa M., Niiya K., et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis: 2002; 13 6 555 559
14. Koyama T., Saito T., Kusano T., Hirosawa S. Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol: 1995; 89 4 893 896
15. Streiff M. B., Ness P. M. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion: 2002; 42 1 18 26
16. Bänninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol: 1993; 85 3 528 532 (Pubitemid 23349056)
17. Ortel T. L., Mercer M. C., Thames E. H., Moore K. D., Lawson J. H. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg: 2001; 233 1 88 96 (Pubitemid 32043608)
18. Lu L., Liu Y., Wei J., Zhang L., Zhang L., Yang R. Acquired inhibitor of factor V: first report in China and literature review. Haemophilia: 2004; 10 5 661 664 (Pubitemid 39317776)
19. Leus B., Devreese K., van den Bossche J., Malfait R. Factor V inhibitor: case report. Blood Coagul Fibrinolysis: 2006; 17 7 585 587 (Pubitemid 44434972)
20. Caers J., Reekmans A., Jochmans K., et al. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy: 2003; 35 6 542 544 (Pubitemid 36705650)
21. Bowman L. J., Anderson C. D., Chapman W. C. Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost: 2010; 36 5 477 484
22. Wiwanitkit V. Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost: 2006; 12 4 485 488 (Pubitemid 44359247)
23. Morris C. J., Curry N. Acquired factor V inhibitor in a critically ill patient. Anaesthesia: 2009; 64 9 1014 1017
24. Ang A. L., Kuperan P., Ng C. H., Ng H. J. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost: 2009; 101 5 852 859
25. Kershaw G., Favaloro E. J. Laboratory identification of factor inhibitors: an update. Pathology: 2012; 44 4 293 302
26. Ortel T. L. Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med: 1999; 133 4 326 334 (Pubitemid 29373029)
27. Favaloro E. J., Bonar R., Duncan E., et al. RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost: 2006; 96 1 73 78 (Pubitemid 44160873)
28. Favaloro E. J., Bonar R., Duncan E., et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology: 2007; 39 5 504 511 (Pubitemid 47454494)
29. Lippi G., Salvagno G. L., Adcock D. M., Gelati M., Guidi G. C., Favaloro E. J. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. Int J Lab Hematol: 2010; 32 1 Pt 2 132 138
30. Fu Y. X., Kaufman R., Rudolph A. E., Collum S. E., Blinder M. A. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol: 1996; 51 4 315 318 (Pubitemid 26117545)
31. Franchini M., Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost: 2010; 36 5 485 492
32. Jansen M., Schmaldienst S., Banyai S., et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol: 2001; 112 1 91 97 (Pubitemid 32151155)
33. de Raucourt E., Barbier C., Sinda P., Dib M., Peltier J. Y., Ternisien C. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol: 2003; 74 3 187 190 (Pubitemid 37363017)
34. Bayani N., Rugina M., Haddad-Vergnes L., Lelong F. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol: 2002; 71 1 33 36 (Pubitemid 34988583)
35. Lebrun A., Leroy-Matheron C., Arlet J. B., Bartolucci P., Michel M. Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol: 2008; 83 2 163 164
36. Lian E. C., Tzakis A. G., Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol: 2004; 77 4 363 365 (Pubitemid 39578317)
37. Galanakis D. K., Ginzler E. M., Fikrig S. M. Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE). Blood: 1978; 52 5 1037 1046 (Pubitemid 9112696)
38. Marciniak E., Greenwood M. F. Acquired coagulation inhibitor delaying fibrinopeptide release. Blood: 1979; 53 1 81 92 (Pubitemid 9079260)
39. Hoots W. K., Carrell N. A., Wagner R. H., Cooper H. A., McDonagh J. A naturally occurring antibody that inhibits fibrin polymerization. N Engl J Med: 1981; 304 15 857 861 (Pubitemid 11101067)
40. Plow E. F., Edgington T. S. Immune responses to the cleavage-associated neoantigens of fibrinogen in man. Identification and characterization of humoral antibodies specific for cleavage fragments. J Clin Invest: 1975; 56 6 1509 1518
41. Whitaker A. N., McFarlane J. R., Rowe E. A., Lee K., Masci P. P. Measurement of autoantibodies against fibrinogen and fibrin degradation products by enzyme-linked immunoassay. Thromb Haemost: 1985; 53 1 80 85 (Pubitemid 15135240)
42. Michalski A., Kondera-Anasz Z., Gonciarz Z. Autoantibodies against fibrinogen during interferon therapy in patients with chronic viral hepatitis. Ital J Gastroenterol Hepatol: 1995; 2 Suppl 226 227
43. MacLean M. A., Wilson R., Thomson J. A., Krishnamurthy S., Walker J. J. Changes in immunologic parameters in normal pregnancy and spontaneous abortion. Am J Obstet Gynecol: 1991; 165 4 Pt 1 890 895
44. Mammen E. F., Schmidt K. P., Barnhart M. I. Thrombophlebitis migrans associated with circulating antibodies against fibrinogen. A case report. Thromb Diath Haemorrh: 1967; 18 3-4 605 611
45. Mertas A., Kondera-Anasz Z. Antifibrinogen antibodies in serum of blood recipients with post-transfusion reactions. Clin Biochem Rev: 1993; 14 199
46. Ghosh S., McEvoy P., McVerry B. A. Idiopathic autoantibody that inhibits fibrin monomer polymerization. Br J Haematol: 1983; 53 1 65 72 (Pubitemid 13217076)
47. Ruiz-Arguelles A. Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. J Clin Invest: 1988; 82 3 958 963
48. Kondera-Anasz Z. Antibodies against fibrinogen in pregnant women, in post delivery women and in the newborns. Thromb Haemost: 1998; 79 5 963 968 (Pubitemid 28224733)
49. La Spada A. R., Skålhegg B. S., Henderson R., Schmer G., Pierce R., Chandler W. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med: 1995; 333 8 494 497
50. Sié P., Bezeaud A., Dupouy D., et al. An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme. J Clin Invest: 1991; 88 1 290 296
51. Fleck R. A., Rapaport S. I., Rao L. V. Anti-prothrombin antibodies and the lupus anticoagulant. Blood: 1988; 72 2 512 519
52. Galli M., Barbui T. Antithrombin antibodies: detection and its significance in the antiphospholipid syndrome. Blood: 1999; 93 2149 2157 (Pubitemid 29153614)
53. Bajaj S. P., Rapaport S. I., Barclay S., Herbst K. D. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood: 1985; 65 6 1538 1543 (Pubitemid 15057965)
54. Holm M., Andreasen R., Ingerslev J. Management of bleeding using recombinant factor VIIa in a patient suffering from bleeding tendency due to a lupus anticoagulant-hypoprothrombinemia syndrome. Thromb Haemost: 1999; 82 6 1776 1778
55. Castro O., Farber L. R., Clyne L. P. Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med: 1972; 77 4 543 548
56. Largo R., Sigg P., von Felten A., Straub P. W. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol: 1974; 26 1 129 140
57. Ozsoylu S., Ozer F. L. Acquired factor IX deficiency. A report of two cases. Acta Haematol: 1973; 50 5 305 314
58. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost: 2004; 2 6 899 909 (Pubitemid 40185737)
59. Campbell E., Sanal S., Mattson J., et al. Factor VII inhibitor. Am J Med: 1980; 68 6 962 964 (Pubitemid 10114110)
60. Delmer A., Horellou M. H., Andreu G., et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood: 1989; 74 1 229 232 (Pubitemid 19187433)
61. Rao L. V., Zivelin A., Iturbe I., Rapaport S. I. Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost: 1994; 72 3 363 371 (Pubitemid 24280773)
62. Smith S. V., Liles D. K., White G. C. II, Brecher M. E. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol: 1998; 57 3 245 252 (Pubitemid 28139245)
63. Kamikubo Y., Miyamoto S., Iwasa A., Ishii M., Okajima K. Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding. Thromb Haemost: 2000; 83 1 60 64 (Pubitemid 30045478)
64. Goodrick M. J., Prentice A. G., Copplestone J. A., Pamphilon D. H., Boon R. J. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol: 1992; 45 4 352 353
65. Reece E. A., Clyne L. P., Romero R., Hobbins J. C. Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature. Arch Intern Med: 1984; 144 3 525 529 (Pubitemid 14152736)
66. Bortoli R., Monticielo O. A., Chakr R. M., et al. Acquired factor XI inhibitor in systemic lupus erythematosus-case report and literature review. Semin Arthritis Rheum: 2009; 39 1 61 65
67. Fukue H., Anderson K., McPhedran P., Clyne L., McDonagh J. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood: 1992; 79 1 65 74
68. Lorand L., Maldonado N., Fradera J., Atencio A. C., Robertson B., Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol: 1972; 23 1 17 27
69. Lorand L., Velasco P. T., Murthy S. N., Lefebvre P., Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood: 1999; 93 3 909 917 (Pubitemid 29067856)
70. Daly H. M., Carson P. J., Smith J. K. Intracerebral haemorrhage due to acquired factor XIII inhibitor-successful response to factor XIII concentrate. Blood Coagul Fibrinolysis: 1991; 2 4 507 514
71. Luo Y. Y., Zhang G. S. Acquired FXIII inhibitor: clinical features, treatment, fibrin structure and epitope determination. Haemophilia: 2011; 17 393 398
72. Ajzner E., Schlammadinger A., Kerényi A., et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood: 2009; 113 3 723 725
73. Karimi M., Bereczky Z., Cohan N., Muszbek L. Factor XIII deficiency. Semin Thromb Hemost: 2009; 35 4 426 438
74. Favaloro E. J. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost: 2010; 36 4 458 467
75. Favaloro E. J., Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med: 2011; 49 5 755 757
76. Favaloro E. J., Lippi G., Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology: 2011; 43 7 682 692
77. Peyvandi F., Favaloro E. J. Rare bleeding disorders. Semin Thromb Hemost: 2009; 35 4 345 347
78. Peyvandi F., Palla R., Menegatti M., Mannucci P. M. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost: 2009; 35 4 349 355
79. de Moerloose P., Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost: 2009; 35 4 356 366
80. Lancellotti S., De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost: 2009; 35 4 367 381
81. Asselta R., Peyvandi F. Factor V deficiency. Semin Thromb Hemost: 2009; 35 4 382 389
82. Mariani G., Bernardi F. Factor VII deficiency. Semin Thromb Hemost: 2009; 35 4 400 406
83. Menegatti M., Peyvandi F. Factor X deficiency. Semin Thromb Hemost: 2009; 35 4 407 415
84. Duga S., Salomon O. Factor XI deficiency. Semin Thromb Hemost: 2009; 35 4 416 425
85. Karimi M., Bereczky Z., Cohan N., Muszbek L. Factor XIII deficiency. Semin Thromb Hemost: 2009; 35 4 426 438